Novo Nordisk A/S (NYSE:NVO) Trading Up 1.1%

Novo Nordisk A/S (NYSE:NVO)’s share price was up 1.1% during trading on Friday . The company traded as high as $139.74 and last traded at $139.09. Approximately 911,015 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 4,356,280 shares. The stock had previously closed at $137.52.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on NVO shares. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, August 19th. Argus increased their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. The Goldman Sachs Group initiated coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target for the company. Finally, StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 19th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus target price of $145.17.

Novo Nordisk A/S Trading Up 0.6 %

The stock has a market cap of $621.07 billion, a PE ratio of 47.67, a price-to-earnings-growth ratio of 1.33 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The stock has a 50-day moving average price of $135.88 and a two-hundred day moving average price of $131.89.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). The firm had revenue of $9.82 billion during the quarter, compared to the consensus estimate of $9.91 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.38 earnings per share for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were paid a dividend of $0.5126 per share. This represents a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, August 16th. Novo Nordisk A/S’s dividend payout ratio is presently 24.83%.

Hedge Funds Weigh In On Novo Nordisk A/S

Large investors have recently bought and sold shares of the business. 1620 Investment Advisors Inc. bought a new position in Novo Nordisk A/S in the second quarter worth approximately $25,000. Gilliland Jeter Wealth Management LLC raised its stake in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after buying an additional 120 shares in the last quarter. Strategic Investment Solutions Inc. IL purchased a new position in Novo Nordisk A/S in the second quarter worth $25,000. First PREMIER Bank purchased a new position in Novo Nordisk A/S in the first quarter worth $25,000. Finally, Dixon Mitchell Investment Counsel Inc. purchased a new position in Novo Nordisk A/S in the first quarter worth $26,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.